PMID- 35928897
OWN - NLM
STAT- MEDLINE
DCOM- 20220808
LR  - 20220825
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Short-time intensive insulin therapy upregulates 3 beta- and 17 
      beta-hydroxysteroid dehydrogenase levels in men with newly diagnosed T2DM.
PG  - 894743
LID - 10.3389/fendo.2022.894743 [doi]
LID - 894743
AB  - OBJECTIVE: Our previous study has found that short-term intensive insulin therapy 
      in patients with newly diagnosed type 2 diabetes mellitus (T2DM) increased serum 
      testosterone levels, but the underlying mechanisms remain unclear. DESIGN AND 
      METHODS: In this self-controlled study, 43 men with newly diagnosed drug naive 
      T2DM, aged 18-60 years, with HbA(1c >)9.0% were treated with continuous 
      subcutaneous insulin infusion (CSII) to normalize blood glucose within one week. 
      Venous blood specimens were collected for measuring of serum total testosterone, 
      dehydroepiandrosterone sulfate (DHEA-S), 3beta- and 17beta-hydroxysteroid dehydrogenase 
      (3beta- and 17beta-HSD) concentrations before and after insulin therapy. RESULTS: 
      Testosterone increased from 13.0 (11.3, 14.6) nmol/L to 15.7 (13.9, 17.5) nmol/L 
      after intensive insulin therapy (p<0.001), while the levels of DHEA-S decreased 
      significantly after treatment (from 6.5 (5.7, 7.3) mumol/L to 6.0 (5.3, 6.7) 
      mumol/L, p=0.001). The ratio of testosterone/DHEA-S increased significantly (2.4 
      (2.0, 2.8) vs. 3.1 (2.6, 3.7) nmol/mumol, p<0.001). After blood glucose 
      normalization with the short-term CSII therapy, 3beta-HSD increased from 11.0 (9.5, 
      12.5) pg/mL to 14.6 (13.5, 15.7) pg/mL, p=0.001, and 17beta-HSD increased from 20.7 
      (16.3, 25.2) pg/mL to 28.2 (23.8, 32.5) pg/mL, p=0.009. CONCLUSIONS: Blood 
      glucose normalization via short-term intensive insulin therapy increases plasma 
      total testosterone levels in men with newly diagnosed type 2 diabetes, associated 
      with a decreased level of DHEA-S, probably because of the enhanced conversion 
      from DHEA to testosterone catalyzed by 3beta-HSD and 17beta-HSD.
CI  - Copyright (c) 2022 Hu, Wang, Cai, Liu, Li, Ma and Ding.
FAU - Hu, Yun
AU  - Hu Y
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
AD  - Department of Endocrinology, Wuxi People's Hospital Affiliated to Nanjing Medical 
      University, Wuxi, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Cai, Ting-Ting
AU  - Cai TT
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Liu, Lu
AU  - Liu L
AD  - Department of Endocrinology, Chunjiang People's Hospital, Changzhou, China.
FAU - Li, Dong-Mei
AU  - Li DM
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Ma, Jian-Hua
AU  - Ma JH
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
FAU - Ding, Bo
AU  - Ding B
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220719
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 3XMK78S47O (Testosterone)
RN  - 459AG36T1B (Dehydroepiandrosterone)
RN  - EC 1.1.- (17-Hydroxysteroid Dehydrogenases)
RN  - EC 1.1.1.51 (3 (or 17)-beta-hydroxysteroid dehydrogenase)
SB  - IM
MH  - 17-Hydroxysteroid Dehydrogenases
MH  - Blood Glucose
MH  - Dehydroepiandrosterone
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Humans
MH  - *Insulin
MH  - Male
MH  - Testosterone
PMC - PMC9344891
OTO - NOTNLM
OT  - beta-hydroxysteroid dehydrogenase
OT  - dehydroepiandrosterone sulfate
OT  - diabetes mellitus
OT  - insulin
OT  - testosterone
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/06 06:00
MHDA- 2022/08/09 06:00
PMCR- 2022/01/01
CRDT- 2022/08/05 02:20
PHST- 2022/03/12 00:00 [received]
PHST- 2022/06/29 00:00 [accepted]
PHST- 2022/08/05 02:20 [entrez]
PHST- 2022/08/06 06:00 [pubmed]
PHST- 2022/08/09 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.894743 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Jul 19;13:894743. doi: 
      10.3389/fendo.2022.894743. eCollection 2022.